Corporate Social Responsibility Report

Overview

The report describes Fosun Pharma's 2017 growth, including group revenue of RMB18,533.5554 million and continued investment in pharmaceutical R&D. It highlights injectable artesunate sales exceeding 100 million and support for more than 20 million critical malaria patients. Environmental disclosures include 820,000 tons of greenhouse gases (CO2), alongside group energy, water, and waste data. The report also describes RMB11.14 million in community donations and includes an independent SGS assurance statement.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2017
Period: 1 January 2017 – 31 December 2017
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis
Matrix

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services

Overview